Description
Biotinylated Tacrolimus Antibody
| Catalog number: | B2010726 |
| Lot number: | Batch Dependent |
| Expiration date: | Batch Dependent |
| Amount: | 50 g |
| Concentration: | 1 mg/mL |
| Supplied as: | Liquid |
| Storage: | 20C |
| Keywords: | Tacrolimus MAB biotin, FK506 antibody biotin |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 Mcm) and are filtered through 0.22 m. |
Biotinylated Tacrolimus Antibody is a high-affinity reagent designed for sensitive detection of tacrolimus (FK506), a critical immunosuppressant used in organ transplantation and autoimmune disease management. This monoclonal antibody is conjugated to biotin, enabling efficient capture and detection in streptavidin-based assay systems such as ELISA, CLIA, and lateral flow platforms. Supplied at 1 mg/mL in liquid format, this reagent supports both manual and automated workflows for therapeutic drug monitoring and assay development.
Biotinylation enhances assay flexibility, allowing for modular integration into multiplexed platforms and sandwich immunoassays. The antibody exhibits high specificity for tacrolimus, with minimal cross-reactivity, making it suitable for pharmacokinetic profiling, toxicity screening, and clinical research. Researchers and assay developers use this reagent to quantify tacrolimus levels in whole blood, serum, or plasma, supporting precision medicine and transplant monitoring.
This antibody is formulated in ultrapure water and filtered through 0.22 m membranes to ensure purity and reproducibility. It is particularly useful in applications requiring high sensitivity and low background, including pediatric and renal transplant studies, ulcerative colitis monitoring, and rheumatoid arthritis research.
Key benefits:
- Monoclonal antibody conjugated to biotin for streptavidin-based detection
- Supports ELISA, CLIA, and lateral flow assay development
- High specificity for tacrolimus with minimal cross-reactivity
- Biotechnology grade; filtered through 0.22 m membranes
- Supplied at 1 mg/mL; store at 20C to maintain activity
Products are for in vitro research use only (RUO).
References
- Tremblay S, Alloway RR. Evaluation of tacrolimus formulations. AAPS J. 2017 Sep;19(5):13321347.
- Undre N et al. Tacrolimus quantitation via microsampling. Ther Drug Monit. 2021 Jun;43(3):364370.
- Hooks MA. Review of tacrolimus as immunosuppressant. Ann Pharmacother. 1994 Apr;28(4):501511.
- Nakase H. Tacrolimus therapy for ulcerative colitis. Nihon Shokakibyo Gakkai Zasshi. 2013 Nov;110(11):19161921.
- Curran MP, Perry CM. Tacrolimus in rheumatoid arthritis. Drugs. 2005;65(7):9931001.
- Cross SA, Perry CM. Once-daily tacrolimus in transplant prophylaxis. Drugs. 2007;67(13):19311943.
- Piotti G et al. Tacrolimus formulations for kidney transplantation. J Nephrol. 2017 Feb;30(1):5361.
- Bowman LJ, Brennan DC. Tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008 Mar;9(4):635643.
- Gianni LM, Sulli MM. Topical tacrolimus for atopic dermatitis. Ann Pharmacother. 2001 JulAug;35(78):943946.
- Reding R. Tacrolimus in pediatric liver transplantation. Pediatr Transplant. 2002 Dec;6(6):447451.
